Media

Corgentech Plans Meeting With FDA to Discuss Registration Strategy Prior to Unblinding of Phase 3 Trial

SOUTH SAN FRANCISCO, Calif., Feb 24, 2005 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK) today announced its intention to meet with the Food and Drug Administration (FDA) prior to the unblinding and announcement of the clinical data from its Phase 3 trial of edifoligide (E2F Decoy) for coronary artery bypass graft (CABG) failure, known as PREVENT IV. Corgentech and Bristol-Myers Squibb (BMS) are meeting with outside experts to discuss various possible regulatory pathways for product approval of edifoligide (E2F Decoy). The meeting with the FDA is expected to occur by the end of March. Whether the PREVENT IV data will be unblinded and announced prior to the end of March, as was previously anticipated, will depend on the timing and results of the meeting with the FDA.

PREVENT IV is a Phase 3 clinical trial evaluating edifoligide (E2F Decoy) for the prevention of vein graft failure and involving 2,400 patients undergoing CABG surgeries at over 100 centers across the United States. Edifoligide (E2F Decoy) has received FDA Fast Track designation for the prevention of vein graft failure. Corgentech and BMS have an agreement to jointly develop and commercialize edifoligide (E2F Decoy), as well as co-promote the product in the U.S.

About Corgentech

Corgentech is a biopharmaceutical company engaged in the discovery, development and commercialization of a new class of therapeutics called transcription factor decoys, or TF decoys. We are creating a pipeline of novel therapeutics based on our proprietary TF decoy technology, focused initially on the treatment of cardiovascular disease, inflammatory disease, and cancer. For more information on the company and its technology, visit www.corgentech.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Act of 1995. These include without limitation statements related to the timing and scheduling of meetings with the FDA, regulatory strategy, our clinical trials, product candidates, and operations. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "slated," "goal" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon our current expectations. Forward-looking statements involve risks and uncertainties. Our actual results could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, including, without limitation, the timing and results of the company's meeting with the FDA as well as those risks and uncertainties detailed in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2003 and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2004. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Corgentech undertakes no obligation to revise or update any forward-looking statements as a result of new information, future events or otherwise after the date hereof.

SOURCE Corgentech Inc.

Jennifer Cook Williams, Senior Director, Investor Relations, of Corgentech Inc.,
+1-650-624-9600, or [email protected]

http://www.prnewswire.com

News Provided by COMTEX